PharVision Advisers’s New York Times NYT Stock Holding History

PharVision Advisers’s Portfolio NYT Stock Details NYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,294	Closed	-$361K	–	911
2025 Q3	$361K	Buy	+6,294	New	+$359K	0.2%	124
2025 Q2	–	Sell	-6,701	Closed	-$332K	–	380
2025 Q1	$332K	Buy	6,701 +1,088	+19%	+$54.7K	0.46%	77
2024 Q4	$292K	Buy	+5,613	New	+$306K	0.25%	166

Other funds holding NYT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

PharVision Advisers's NYT Position: Q4 2025 in Review

PharVision Advisers sold out of New York Times (NYT) in Q4 2025, closing a stake of 6,294 shares — an estimated $361K sold.

PharVision Advisers first reported a position in NYT in Q4 2024 and held it in 3 quarters. The position peaked at $361K in Q3 2025. 553 funds tracked by Wall St. Rank hold NYT as of Q4 2025.

PharVision Advisers reported no remaining New York Times position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 6,294 New York Times shares in Q4 2025, an estimated $361K.
PharVision Advisers first reported a position in New York Times in Q4 2024 and held it in 3 quarters.
PharVision Advisers's New York Times position peaked at $361K in Q3 2025.
553 funds tracked by Wall St. Rank held New York Times as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.